Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination.
“We are disappointed by the CHMP opinion. However, we remain confident in the benefit-risk profile of istradefylline and are committed to making a difference to the lives of people living with Parkinson’s, an area which has had few innovative therapies for decades,” said Abdul Mullick, President of Kyowa Kirin International. “There are currently few new treatment options available to manage end-of-dose motor fluctuations in Parkinson’s, and we believe that istradefylline offers people living with the condition a chance to regain some control over the management of their ‘OFF’ time. We remain committed to pursuing the registration of istradefylline in the EU.”
“Parkinson’s is a complex condition that affects every person living with it differently and is characterised by a broad range of symptoms that can significantly impact their quality of life,” said Professor Heinz Reichmann, Professor and Chair of the Neurology Department at the University of Dresden. “There is currently an urgent need for innovative treatments such as istradefylline for people living with Parkinson’s, to support them and their families in reducing their ‘OFF’ time. I hope that the CHMP will reconsider their position on istradefylline.”
“First of all, I would like to appreciate those who have contributed to the development of istradefylline.” Said Tomohiro Sudo, Executive Officer, Head of Global Product Strategy Department at Kyowa Kirin. “Although unfortunately it is a negative opinion from the CHMP this time, we will continue to think of how we can contribute to people living with Parkinson’s and their families as we do in the US and Japan.”
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
About istradefylline
Istradefylline is a novel, first-in-class non-dopaminergic, adenosine A2A receptor antagonist that reduces ‘OFF’ time in people living with Parkinson’s through selective targeting of adenosine A2A receptors in the basal ganglia. Whilst dopaminergic treatment targets the dopamine receptors in the direct and indirect pathways to facilitate movement, istradefylline, as an add-on to L-Dopa, reduces the activity of the indirect pathway which suppresses movement. Therefore, it helps restore the balance within the basal ganglia.1,2
Istradefylline has been approved for use in Japan by the Ministry of Health, Labour and Welfare since 2013, under the brand name of NOURIAST®. In August 2019 it also received approval from the U.S. Food and Drug Administration (FDA) as adjunctive treatment to levodopa / carbidopa in adult patients with Parkinson’s experiencing “OFF” episodes and is marketed under the name of NOURIANZ®.3,4
About Parkinson’s and ‘OFF’ episodes
Parkinson’s is a chronic, progressive neurodegenerative condition that affects small regions in the brain that control movement, balance and posture.5 It is the fastest growing neurodegenerative disorder in the world,6 with an estimated 10 million people in the world currently living with the condition.7 Although it is classically characterised by motor symptoms (symptoms involving movement), people living with Parkinson’s also experience a large range of non-motor symptoms, which add to the complexity of living with the condition.5 Although Parkinson’s is not life threatening there is currently no cure. Over time symptoms progress and can be unpredictable, imposing a significant impact on daily life.5 This impact can extend to caregivers, friends and family, whose own wellbeing and quality of life can deteriorate as a result.8
‘OFF’ episodes is used to describe the return of Parkinson’s symptoms, also known as ‘OFF’ symptoms, and can be triggered by a variety of phenomena, including:9
- Delayed onset of response to medication
- Reduced duration of benefit from a medication
- Reduced or no efficacy of a dose of medication
About Kyowa Kirin International in neurology
Kyowa Kirin International is committed to building meaningful partnerships with the wider Parkinson’s community and is working with healthcare professionals, government agencies, policymakers and patient advocacy groups to improve care and support for people living with Parkinson’s.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
Kyowa Kirin International
http://www.international.kyowa-kirin.com/
Galabank Business Park
Galashiels, TD1 1QH
United Kingdom
References
1 Jenner P, Mori A, Aradi S.D, et al. Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 2021, doi:10.1080/14737175.2021.1880896.
2 LeWitt P, Aradi S, Hauser R, et al. The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Related Disord 2020;80(Supple 1):S54–S63.
3 Ministry of Health, Labour and Welfare. NOURIAST Prescribing Information. Available at http://docplayer.net/43410136-Nouriast-tablets-20-mg.html [Last accessed: July 2021].
4 FDA. NOURIANZ Prescribing Information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf [Last accessed: July 2021].
5 European Parkinson’s Disease Association. About Parkinson’s. Available from: https://www.epda.eu.com/about-parkinsons/what-is-parkinsons/ [Last accessed: July 2021].
6 GBD 2016 Parkinson’s Disease Collaborator Group. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:939–953.
7 Ball N et al. Parkinson’s Disease and the Environment. Front Neurol 2019;10:1-8 [Last accessed: July 2021].
8 Armstrong MJ, Rastgardani T, Gagliardi AR, et al. The impact of off periods on persons with Parkinson’s and care partners: a qualitative study. Neurol Clin Pract 2020;10.1212/CPJ.0000000000000921.
9 Freitas M, Hess C, Fox S. Motor complication of dopaminergic medications in Parkinson’s disease. Semin Neurol 2017;33(2):147-157.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210723005347/en/
Contact information
Contacts for Kyowa Kirin International:
Media
Sarah Evans
Email: Sarah.Evans@kyowakirin.com
Contacts for Kyowa Kirin Co., Ltd.:
Media
Hiroki Nakamura
Email: media@kyowakirin.com
KKI/INT/IST/0141
Date of preparation: July 2021
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT and E.ON Extend Partnership to Drive AI-Powered Energy Management Innovation11.11.2025 03:00:00 EET | Press release
Global technology and IT services provider FPT and E.ON Optimum, the digital solutions arm of E.ON UK, under E.ON Group, announced a new agreement to extend their collaboration in digital energy management. The signing marks the next phase of a partnership established in 2022, reaffirming both corporations’ shared vision of harnessing technology to accelerate innovation and sustainability in the energy sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110039775/en/ FPT and E.ON Optimum leaders at the signing ceremony to extend their partnership in AI-powered energy management. Under this agreement, FPT will continue to support the development and operation of E.ON Optimum’s solution platform, a cloud-based energy management system that gives business energy users timely, flexible data analysis, allowing for better and faster decisions on net-zero energy usage. The next phase focuses on maintaining and enhancing web a
Ant International Open Sources Time-Series Transformer AI Model to Enable More Businesses to Benefit from AI-Powered Forecasting11.11.2025 02:30:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has released its proprietary Falcon TST (Time-Series Transformer) AI model, the industry-first Mixture of Experts architecture-based big data model with multiple patch tokenizers, supported by up to 2.5 billion parameters. The model has also achieved state-of-the-art zero-shot results on well-acknowledged long-term forecasting benchmarks, such as absolute mean error rates. Deployed internally at Ant International to manage cashflow and FX exposure on an hourly, daily and weekly basis, Falcon TST has achieved accuracy rates of over 90%, and cut the company’s FX costs by up to 60%. Ant International also collaborated with various industry partners to deploy the model in different use cases, such as in helping businesses mitigate FX cost and volatility, as well as to support airlines in offering more stable, competitive pricing to their customers. With the Airports Council International W
The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100 th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More11.11.2025 01:08:00 EET | Press release
The Empire State Building (ESB) today announced its Holiday Celebration plans include: holiday décor, classic movie screenings, local pop-ups, festive tower lightings, and a holiday takeover with the Radio City Rockettes to celebrate the most wonderful time of the year at New York City’s number one attraction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110124149/en/ The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More “There is no better place to celebrate the holidays in New York City than at the Empire State Building Observatory,” said Dan Rogoski, General Manager at the Empire State Building Observatory. “This year, New Yorkers and visitors will enjoy the best of the holiday season in our iconic venue as we celebrate 100 years of the Radio City Rockettes.” Deck the Halls From the grou
Megaport to Acquire Latitude.sh, Creating an Industry-leading Compute and Network-as-a-Service Platform to Power High-performance Applications and AI Workloads Globally11.11.2025 00:17:00 EET | Press release
Megaport Limited (ASX: MP1), the world’s leading Network-as-a-Service (NaaS) provider, today announced it has entered into an agreement to acquire Latitude.sh, a leading global Compute-as-a-Service company delivering high-performance CPU and GPU infrastructure on demand. Following completion of the acquisition, the combined capabilities will create a global platform that unites Megaport’s private, high-speed connectivity fabric with Latitude.sh’s compute infrastructure, enabling enterprises to rapidly deploy and connect critical workloads across more than 1,000 data centres in 26 countries. “Megaport has long been trusted by the world’s largest enterprises to move workloads seamlessly between data centers and the cloud,” said Michael Reid, CEO of Megaport. “By bringing Latitude.sh into the fold, we’re extending that promise beyond the network, and into high-performance, optimized compute, complementing cloud providers. Together, we will not only serve the massive traditional compute ma
Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization10.11.2025 23:49:00 EET | Press release
Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future. This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets. A Strategic Step Toward Circular Bioeconomy Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom